Carminomycin II (BioDeep_00000177048)

   

human metabolite blood metabolite


代谢物信息卡片


8-acetyl-10-[(4-amino-5-{3-hydroxy-1-[(1-hydroxypropan-2-yl)oxy]butoxy}-6-methyloxan-2-yl)oxy]-1,6,8,11-tetrahydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione

化学式: C33H41NO13 (659.2577776)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(O)CC(OC(C)CO)OC1C(N)CC(OC2CC(O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(O)C=CC=C2C4=O)C(C)=O)OC1C
InChI: InChI=1S/C33H41NO13/c1-13(36)8-22(44-14(2)12-35)47-32-15(3)45-23(9-19(32)34)46-21-11-33(43,16(4)37)10-18-25(21)31(42)27-26(29(18)40)28(39)17-6-5-7-20(38)24(17)30(27)41/h5-7,13-15,19,21-23,32,35-36,38,40,42-43H,8-12,34H2,1-4H3

描述信息

D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
D004791 - Enzyme Inhibitors

同义名列表

16 个代谢物同义名

8-acetyl-10-[(4-amino-5-{3-hydroxy-1-[(1-hydroxypropan-2-yl)oxy]butoxy}-6-methyloxan-2-yl)oxy]-1,6,8,11-tetrahydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; 8-acetyl-10-[(4-amino-5-{3-hydroxy-1-[(1-hydroxypropan-2-yl)oxy]butoxy}-6-methyloxan-2-yl)oxy]-1,6,8,11-tetrahydroxy-9,10-dihydro-7H-tetracene-5,12-dione; Hydrochloride, carubicin; Carubicin Hydrochloride; Demethyldaunorubicin; Demethyldaunomycin; Carminomycin III; Carminomycin II; Carminomycin I; Rubeomycin a1; Carminomicin; Karminomicin; Rubeomycin a; Karminomycin; Carminomycin; Carubicin



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Girma M Woldemichael, Thomas J Turbyville, W Marston Linehan, James B McMahon. Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Cancer research. 2011 Jan; 71(1):134-42. doi: 10.1158/0008-5472.can-10-0757. [PMID: 21199801]
  • N G Prokof'eva, M M Anisimov, M I Kiseleva, N M Rebachuk, N D Pokhilo. [Cytotoxic activity of dammarane triterpenoids from birch leaves]. Izvestiia Akademii nauk. Seriia biologicheskaia. 2002 Nov; ?(6):645-9. doi: ". [PMID: 12561324]
  • S J Park, A H Kaye, J S Hill. An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2000 Jan; 7(1):42-7. doi: 10.1054/jocn.1998.0131. [PMID: 10847650]
  • K Clarke, R L Basser, D Maher, D J Morgan, J Cebon, R M Fox, J S Hill, C Alt, J Bartlett, H Geldard, A H Kaye, M D Green. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jun; 16(6):2181-7. doi: 10.1200/jco.1998.16.6.2181. [PMID: 9626219]
  • D J Morgan, J S Hill, K Clarke, S S Stylli, S J Park, J Cebon, R L Basser, A H Kaye, H Geldard, D W Maher, M D Green. Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. Cancer chemotherapy and pharmacology. 1998; 41(5):423-6. doi: 10.1007/s002800050761. [PMID: 9523740]
  • W Z Zhang, W Cosolo, J Zalcberg. In vitro binding of MX2 (KRN8602) and epirubicin to human plasma protein. Pharmacology. 1997 Dec; 55(6):279-84. doi: 10.1159/000139539. [PMID: 9413856]
  • D J Morgan, J S Hill, K Clarke, S S Stylli, S J Park, J Cebon, R L Basser, A H Kaye, H Geldard, D W Maher, M D Green. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Cancer chemotherapy and pharmacology. 1997; 40(3):202-8. doi: 10.1007/s002800050647. [PMID: 9219502]
  • H Shinkai, H Takahashi, K Miyamoto, T Uchida, T Tokiwa. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice. Cancer chemotherapy and pharmacology. 1996; 38(5):417-24. doi: 10.1007/s002800050505. [PMID: 8765434]
  • A A Ebrahim el-Zayat, M A Izquierdo, G M Clark, D D Von Hoff. Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro. Investigational new drugs. 1995; 13(2):125-131. doi: 10.1007/bf00872860. [PMID: 8617574]
  • H Yamamoto, N Arita, T Ohnishi, S Hiraga, S Izumoto, T Taki, M Higuchi, T Hayakawa, H Shinkai. [Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection]. Gan to kagaku ryoho. Cancer & chemotherapy. 1993 Jul; 20(9):1227-30. doi: NULL. [PMID: 8333749]
  • V A Gorbunova. [Experience with using carminomycin in oncological clinical practice]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 1992 Mar; 37(3):35-9. doi: NULL. [PMID: 1325145]
  • H Majima, H Shinkai. [Pharmacokinetics of KRN 8602 in cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 1991 Dec; 18(15):2589-95. doi: NULL. [PMID: 1746971]
  • Y Sato, L Eddy, P Hochstein. Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochemical pharmacology. 1991 Nov; 42(12):2283-7. doi: 10.1016/0006-2952(91)90231-s. [PMID: 1764113]
  • H Shinkai, H Takahashi, K Kikuchi, H Kawai, N Otake. Determination of the new morpholino anthracycline MX2.HCl and its metabolites in biological samples by high-performance liquid chromatography. Journal of chromatography. 1991 Sep; 570(1):203-8. doi: 10.1016/0378-4347(91)80217-z. [PMID: 1797829]
  • Sh S Tazhibaev, E G Lenskaia, N R Alekseeva, Zh S Sisemalieva, B V Monakhov. [The influence on tumor growth and the function of the thiol-dependent systems of the liver of excess cooking fat and vitamin E in the diet. The effects of carminomycin]. Voprosy pitaniia. 1990 May; ?(3):47-51. doi: ". [PMID: 2399682]
  • P P Constantinides, Y Y Wang, T G Burke, T R Tritton. Transverse location of anthracyclines in lipid bilayers. Paramagnetic quenching studies. Biophysical chemistry. 1990 Apr; 35(2-3):259-64. doi: 10.1016/0301-4622(90)80013-w. [PMID: 2168766]
  • J Kuratsu, Y Mihara, M Kochi, S Takaki, Y Ushio. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells]. Gan to kagaku ryoho. Cancer & chemotherapy. 1989 Mar; 16(3 Pt 1):399-403. doi: . [PMID: 2930204]
  • Sh S Tazhibaev, E G Lenskaia, K Kh Khasenova, N M Karsybekova, N R Alekseeva. [Effect of carminomycin on the enzyme systems of the metabolism of active forms of oxygen and on free-radical lipid oxidation in August rats with Walker carcinosarcoma 256]. Eksperimental'naia onkologiia. 1989; 11(4):66-70. doi: ". [PMID: 2759014]
  • M I Reznikova, Iu V Dudnik. [Semisynthetic derivatives of daunorubicin and carminomycin: inhibition of DNA synthesis after intravenous administration to mice]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 1988 Sep; 33(9):653-7. doi: NULL. [PMID: 3218988]
  • S Izumoto, N Arita, Y Ushio, T Hayakawa, T Ohnishi, T Taki, H Yamamoto, Y Oku, H Mogami, N Komeshima. [Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats]. Gan to kagaku ryoho. Cancer & chemotherapy. 1988 May; 15(5):1765-9. doi: . [PMID: 3369870]
  • M I Reznikova, Iu V Dudnik. [Suppression of DNA synthesis in mice by the anthracycline antibiotics daunorubicin, carminomycin and doxorubicin]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 1988 Apr; 33(4):286-9. doi: NULL. [PMID: 3389958]
  • A I Suslova, I A Gorskaia, I D Sheveleva, T V Kaverinskaia, L M Tsofina. [Relation between respiration and swelling of liver mitochondria induced by anthracycline antibiotics]. Biokhimiia (Moscow, Russia). 1988 Feb; 53(2):227-32. doi: . [PMID: 3163503]
  • T G Burke, T R Tritton. Ligand self-association at the surface of liposomes: a complication during equilibrium-binding studies. Analytical biochemistry. 1984 Nov; 143(1):135-40. doi: 10.1016/0003-2697(84)90567-0. [PMID: 6597683]
  • H Weenen, H M Pinedo, M M de Planque, W W Ten Bokkel Huinink, J G McVie, J Lankelma. Pharmacokinetics of carminomycin in man: biweekly schedule vs single dose every three weeks. European journal of cancer & clinical oncology. 1984 Jul; 20(7):915-8. doi: 10.1016/0277-5379(84)90164-0. [PMID: 6540192]
  • M J Oosterbaan, R J Dirks, T B Vree, E van der Kleijn. Rapid quantitative determination of seven anthracyclines and their hydroxy metabolites in body fluids. Journal of chromatography. 1984 Mar; 306(?):323-32. doi: 10.1016/s0378-4347(00)80894-4. [PMID: 6585367]
  • O E Vatin. [Effect of rubomycin and carminomycin on suppressor cells participating in the regulation of the immune response]. Antibiotiki. 1983 Apr; 28(4):307-11. doi: NULL. [PMID: 6222694]
  • A V Poteshnykh, V E Shevchenko. [Determination of carminomycin and its basic metabolite 13-dihydrocarminomycin by a highly efficient liquid chromatographic method with a fluorescent detector]. Antibiotiki. 1982 Nov; 27(11):820-3. doi: . [PMID: 7181464]
  • J Lankelma, P G Penders, J G McVie, A Leyva, W W Ten Bokkel-Huinink, M M de Planque, H M Pinedo. Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography. European journal of cancer & clinical oncology. 1982 Apr; 18(4):363-7. doi: 10.1016/0277-5379(82)90007-4. [PMID: 6889513]
  • N G Shepelevtsev, L E Gol'dberg, E N Olsuf'eva, L S Povarov. [Acute toxicity of the N-acyl derivatives of carminomycin and rubomycin]. Antibiotiki. 1982 Jan; 27(1):57-61. doi: . [PMID: 7059147]
  • S E Fandrich, K A Pittman. Analysis of carminomycin in human serum by fluorometric high-performance liquid chromatography. Journal of chromatography. 1981 Apr; 223(1):155-64. doi: 10.1016/s0378-4347(00)80078-x. [PMID: 7251757]
  • S K Aleksander, V A Liashenko, I V Iakushkina. [Comparison of the antitumor, immunodepressive and toxic properties of carminomycin-albumin complexes differing in carminomycin content]. Antibiotiki. 1981 Apr; 26(4):298-302. doi: NULL. [PMID: 6894522]
  • S D Reich, S E Fandrich, T T Finkelstein, J E Schurig, A P Florczyk, R L Comis, S T Crooke. Pharmacokinetics of carminomycin in dogs and humans. Preliminary report. Cancer chemotherapy and pharmacology. 1981; 6(2):189-93. doi: 10.1007/bf00262341. [PMID: 7307236]
  • R A Buroker, D F Johnson, H Madissoo. The toxicological evaluation of carminomycin - an antineoplastic anthracycline antibiotic. Drug and chemical toxicology. 1981; 4(4):383-96. doi: 10.3109/01480548109017829. [PMID: 7344912]
  • E Nissen, R Dettmer, D Fiedler, M Bodammer. [Polyamines and their significance for control of cancer chemotherapy (author's transl)]. Archiv fur Geschwulstforschung. 1980; 50(4):336-40. doi: NULL. [PMID: 7458581]
  • V A Liashenko, S P Shapovalova, S K Aleksander, I V Malkova. [Comparison of the action of carminomycin and rubomycin on the dynamics of the primary and secondary immune responses]. Antibiotiki. 1979 Jun; 24(6):449-54. doi: . [PMID: 572197]
  • J A Merski, Y Daskal, S T Crooke, H Busch. Acute ultrastructural effects of the antitumor antibiotic carminomycin on nucleoli of rat tissues. Cancer research. 1979 Apr; 39(4):1239-44. doi: NULL. [PMID: 421207]
  • V A Liashenko, S P Shapovalova, S K Aleksander, L S Povarov. [Antiviral action of carminomycin and some of its derivatives]. Antibiotiki. 1978 Nov; 23(11):1009-15. doi: NULL. [PMID: 214027]
  • V A Liashenko, S K Aleksander. [Antitumor properties and toxicity of a carminomycin and protein complex]. Antibiotiki. 1978 Nov; 23(11):1005-9. doi: NULL. [PMID: 581438]
  • M I Gar'kavyĭ, F Ia Kovner. [Serum enzymatic activity in oncological patients treated with carminomycin]. Antibiotiki. 1978 Aug; 23(8):756-60. doi: NULL. [PMID: 210711]
  • N P Chuchalina, E D Gol'dberg, B Iu Sal'nik, V A Telesheva. [Role of the adrenal glands in the cytostatic action mechanism of antitumor antibiotics]. Antibiotiki. 1978 Apr; 23(4):362-5. doi: NULL. [PMID: 646337]
  • N G Shepelevtseva, I P Belova, T P Vertogradova, L E Gol'dberg. [Comparative study of the cardiotoxicity of the anthracycline antibiotics, rubomycin, carminomycin and dihydrocarminomycin, in experiments on white mice]. Antibiotiki. 1978 Jan; 23(1):78-87. doi: . [PMID: 623453]
  • M E Wall, M C Wani, H Taylor. Isolation and chemical characterization of antitumor agents from plants. Cancer treatment reports. 1976 Aug; 60(8):1011-30. doi: ". [PMID: 991155]
  • L E Gol'dberg, T P Vertogradova, S T Filippos'iants, I P Belova, E S Stepanova. [Toxicity and pharmacological properties of carminomycin complex components]. Antibiotiki. 1976 May; 21(5):416-22. doi: NULL. [PMID: 1023813]
  • O A Lapchinskaya, T A Saburova, V I Ponomarenko. Production of carminomycin by auxotrophic mutants of Actinomadura carminata. Zeitschrift fur allgemeine Mikrobiologie. 1975; 15(5):383-5. doi: ". [PMID: 1189475]
  • L E Goldberg, S T Filippos'iants, I A Kunrat, E S Stepanova, N G Shepelevtseva. [A study of the toxicity, pharmacokinetics and pharmacodynamics of the new antitumor antibiotic carminomycin]. Antibiotiki. 1974 Jan; 19(1):57-62. doi: NULL. [PMID: 4463841]
  • T P Vertogradova, L E Gol'dberg, S T Filippos'iants, I P Belova, E S Stepanova. [The mechanism of the toxic effect of the antitumor antibiotic carminomycin]. Antibiotiki. 1974 Jan; 19(1):50-7. doi: NULL. [PMID: 4463840]